Get started
Author

Renske Wever

ORCID: 0000-0001-7334-5905
Observed ORCID: 0000-0001-7334-5905
OpenAlex ID: A5033714740
Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model
2020 · Alexander M.M. Eggermont, Domenico Bellomo, et al. · European Journal of Cancer · 49
PDF
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP)
2022 · Teresa Amaral, Tobias Sinnberg, et al. · European Journal of Cancer · 40
Genome-Resolved Metagenomics of a Photosynthetic Bioreactor Performing Biological Nutrient Removal
2021 · Elizabeth A. McDaniel, Renske Wever, et al. · Microbiology Resource Announcements · 11
Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP)
2024 · Ani Pazhava, Wesley Y. Yu, et al. · Annals of Surgical Oncology · 7
PDF
Clinicopathologic models predicting non‐sentinel lymph node metastasis in cutaneous melanoma patients: Are they useful for patients with a single positive sentinel node?
2021 · Barbara Rentroia‐Pacheco, Félicia J. Tjien‐Fooh, et al. · Journal of Surgical Oncology · 5
PDF
Identification of stage IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
2020 · Renske Wever, Félicia Tjien-Fooh, et al. · Journal of Clinical Oncology · 3
Prognostic significance of the CP-GEP assay combining clinicopathologic factors and gene expression profiling in patients (pts) with AJCC v8 stage I/II cutaneous melanoma (CM).
2022 · Teresa Maria Santos Amaral, Tobias Sinnberg, et al. · Journal of Clinical Oncology · 1
Correction: Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP)
2025 · Ani Pazhava, Wesley Y. Yu, et al. · Annals of Surgical Oncology
PDF
Correction: Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP)
2025 · Ani Pazhava, Wesley Y. Yu, et al. · Annals of Surgical Oncology
PDF
ASO Visual Abstract: Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP)
2024 · Ani Pazhava, Wesley Y. Yu, et al. · Annals of Surgical Oncology
PDF
53106 Primary cutaneous melanoma patients stratified by the Merlin assay (CP-GEP): risk of nodal metastasis and long-term survival outcome in a U.S. cohort
2024 · Wesley Yu, Sheena Hill, et al. · Journal of the American Academy of Dermatology
Identification of Stage I and II Melanoma Patients at High Risk for Recurrence Using a Model Combining Clinicopathologic Factors with Gene Expression Profiling (CP-GEP)
2022 · teresa Amaral, Tobias Sinnberg, et al. · SSRN Electronic Journal
Using a clinicopathologic and gene expression model to identify melanoma patients at high risk for disease relapse.
2020 · Alexander M. Eggermont, Domenico Bellomo, et al. · Journal of Clinical Oncology
Works count: 13
Citation count: 116
H-index: 5
I10-index: 3
Year
Topic
Type